ALTERITY THERAPEUTICS-ADR (ATHE) Forecast, Price Target & Analyst Ratings
NASDAQ:ATHE • US02155X2053
3.4 USD
0 (0%)
Last: Mar 4, 2026, 05:20 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALTERITY THERAPEUTICS-ADR (ATHE).
Forecast Snapshot
Consensus Price Target
$3.37
-0.82% Downside
Next Earnings Forecast
Release DateN/A
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.37
Upside
-0.82%
From current price of $3.40 to mean target of $3.37, Based on 5 analyst forecasts
Low
$3.34
Median
$3.37
High
$3.47
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
5 analysts have analysed ATHE and the average price target is 3.37 USD. This implies a price decrease of -0.82% is expected in the next year compared to the current price of 3.4.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
ATHE was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about ATHE.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed ATHE. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-17 | Canaccord Genuity | Initiate | Speculative Buy |
| 2025-01-30 | Maxim Group | Maintains | Buy -> Buy |
| 2024-12-12 | Maxim Group | Initiate | Buy |
| 2024-03-07 | Benchmark | Reiterate | Speculative Buy -> Speculative Buy |
| 2023-06-05 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2022-08-03 | Ladenburg Thalmann | Initiate | Buy |
| 2022-06-23 | Goldman Sachs | Maintains | Neutral |
| 2021-08-20 | Benchmark | Initiate | Speculative Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.4K 556.00% | 268.4K 1,536.59% | 446.3K 66.28% | -100.00% | 8.438M | 35.03M 315.15% | 381.19M 988.18% | 807.11M 111.73% | |||
| EBITDA YoY % growth | N/A | N/A | N/A | -21.412M | -28.583M -33.49% | -35.754M -25.09% | -25.088M 29.83% | 28.826M 214.90% | N/A | N/A | |
| EBIT YoY % growth | -14.622M 8.35% | -19.339M -32.26% | -14.215M 26.49% | -21.513M -51.34% | -28.684M -33.33% | -35.956M -25.35% | -37.324M -3.80% | -12.474M 66.58% | 253.65M 2,133.36% | 622.9M 145.57% | |
| Operating Margin | -89,157.32% | -7,205.10% | -3,185.14% | N/A | N/A | N/A | -442.33% | -35.61% | 66.54% | 77.18% | |
| EPS YoY % growth | N/A | N/A | N/A | -42.74 | -42.74 | -42.74 | -21.45 49.80% | 0.00 100.00% | N/A | N/A |
All data in AUD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in AUD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-323.08%
EPS Next 5 Year
14.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
156.86%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-53.02%
EBIT Next 5 Year
37.35%
ALTERITY THERAPEUTICS-ADR / ATHE Forecast FAQ
What is the price target for ATHE stock?
5 analysts have analysed ATHE and the average price target is 3.37 USD. This implies a price decrease of -0.82% is expected in the next year compared to the current price of 3.4.
Can you provide the analyst count for ALTERITY THERAPEUTICS-ADR stock?
The number of analysts covering ALTERITY THERAPEUTICS-ADR (ATHE) is 5.